Celcuity Is Maintained at Buy by Stifel
Stifel Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $42
Celcuity Price Target Announced at $27.00/Share by LifeSci Capital
Celcuity Analyst Ratings
LifeSci Capital Initiates Coverage on Celcuity With Outperform Rating, $27 Price Target
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $23 to $39
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $23 to $39
Celcuity Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Celcuity Analyst Ratings
Needham Reiterates Buy on Celcuity, Maintains $23 Price Target
Analysts Conflicted on These Healthcare Names: Verrica Pharmaceuticals (VRCA), Celcuity (CELC) and Bluebird Bio (BLUE)
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Celcuity (CELC) and Intuitive Surgical (ISRG)
Celcuity Analyst Ratings
Leerink Partners Initiates Celcuity(CELC.US) With Buy Rating, Announces Target Price $29
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Celcuity (CELC) and Icon (ICLR)
Celcuity Analyst Ratings
Celcuity Inc: Needham cuts price target from $24.00 to $23.00
Stifel Maintains Buy on Celcuity, Maintains $40 Price Target